HK1141708A1 - Agent for treatment of pulmonary disease - Google Patents

Agent for treatment of pulmonary disease

Info

Publication number
HK1141708A1
HK1141708A1 HK10108116.0A HK10108116A HK1141708A1 HK 1141708 A1 HK1141708 A1 HK 1141708A1 HK 10108116 A HK10108116 A HK 10108116A HK 1141708 A1 HK1141708 A1 HK 1141708A1
Authority
HK
Hong Kong
Prior art keywords
agent
treatment
pulmonary disease
pulmonary
disease
Prior art date
Application number
HK10108116.0A
Other languages
English (en)
Inventor
Kensuke Egashira
Junji Kojima
Megumi Sakamoto
Original Assignee
Univ Kyushu Nat Univ Corp
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyushu Nat Univ Corp, Kowa Co filed Critical Univ Kyushu Nat Univ Corp
Publication of HK1141708A1 publication Critical patent/HK1141708A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK10108116.0A 2007-04-27 2010-08-25 Agent for treatment of pulmonary disease HK1141708A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007119553 2007-04-27
JP2007155816 2007-06-13
PCT/JP2008/001081 WO2008139703A1 (ja) 2007-04-27 2008-04-25 肺疾患治療薬

Publications (1)

Publication Number Publication Date
HK1141708A1 true HK1141708A1 (en) 2010-11-19

Family

ID=40001929

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10108116.0A HK1141708A1 (en) 2007-04-27 2010-08-25 Agent for treatment of pulmonary disease

Country Status (10)

Country Link
US (1) US20100086615A1 (pt)
EP (1) EP2140882B1 (pt)
JP (1) JP4896220B2 (pt)
KR (1) KR101530393B1 (pt)
CN (1) CN101668542B (pt)
CA (1) CA2685054C (pt)
ES (1) ES2425969T3 (pt)
HK (1) HK1141708A1 (pt)
PT (1) PT2140882E (pt)
WO (1) WO2008139703A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2526927A1 (de) * 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nano- und Mikropartikel beschichtet mit Stabilisatoren für die pulmonale Applikation
EP2526926A1 (de) * 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation
JP6551825B2 (ja) * 2014-02-10 2019-07-31 公立大学法人首都大学東京 クロマチン構造制御剤
WO2016076227A1 (ja) * 2014-11-10 2016-05-19 正明 伊井 幹細胞機能増強用スタチン封入ナノ粒子製剤、並びにそれを含有する機能増強幹細胞及びその製造方法
KR20200141501A (ko) 2016-05-06 2020-12-18 각코우호징 오사카 이카야쿠카 다이가쿠 염증성 질환 치료용 줄기세포의 기능 강화를 위한 스타틴 봉입 나노입자 제제, 및 이를 함유하는 염증성 질환 치료용 기능 강화 줄기세포
EP3758677A1 (en) * 2018-02-26 2021-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Drug delivery systems
JP2019196342A (ja) * 2018-05-10 2019-11-14 学校法人大阪医科薬科大学 スタチン封入ナノ粒子製剤、それを含有する歯髄由来幹細胞及びそれを含む細胞製剤。
WO2020205663A1 (en) * 2019-03-29 2020-10-08 The Regents Of The University Of California Inhaled statins as bronchodilators to improve lung function in respiratory diseases
WO2021167088A1 (ja) * 2020-02-21 2021-08-26 良和 中岡 肺高血圧症改善用組成物、肺高血圧症の予後予測方法、肺高血圧症の重症度判定補助方法および肺高血圧症の診断補助方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
ZA81703B (en) 1980-02-04 1982-09-29 Merck & Co Inc New antihypercholesterolemic compounds,intermediates and processes
JPS572240A (en) 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
JPS60500015A (ja) 1982-11-22 1985-01-10 サンド・アクチエンゲゼルシヤフト メバロラクトン同族体とその誘導体、これらの製造法およびこれらを含有する製薬学的組成物
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
FR2809112B1 (fr) * 2000-05-16 2004-05-07 Centre Nat Rech Scient Materiaux a base de polymeres biodegradables et son procede de preparation
WO2003049701A2 (en) * 2001-12-10 2003-06-19 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
WO2003077886A1 (fr) * 2002-03-20 2003-09-25 Hosokawa Micron Corporation Procede de fabrication de particules composites contenant un produit chimique
JP4142318B2 (ja) 2002-03-20 2008-09-03 株式会社ホソカワ粉体技術研究所 薬物含有複合粒子の製造方法
JP4831965B2 (ja) * 2002-06-10 2011-12-07 エラン ファーマ インターナショナル，リミティド ＨＭＧ−ＣｏＡ還元酵素インヒビター誘導体（「スタチン」）を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造
JP4707937B2 (ja) 2003-02-28 2011-06-22 ホソカワミクロン株式会社 薬物含有複合粒子の製造方法および経肺製剤
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20040224030A1 (en) * 2003-05-06 2004-11-11 Shastri Venkatram R. Microsphere delivery systems
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050245905A1 (en) * 2004-04-30 2005-11-03 Schmidt Steven P Local drug-delivery system
JP2006321763A (ja) 2005-05-20 2006-11-30 Hosokawa Funtai Gijutsu Kenkyusho:Kk 生体適合性ナノ粒子及びその製造方法
CN101370479A (zh) * 2005-12-16 2009-02-18 堪萨斯州立大学 用于递送治疗剂的纳米团簇
GB0619500D0 (en) * 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis

Also Published As

Publication number Publication date
CN101668542A (zh) 2010-03-10
EP2140882A4 (en) 2010-05-26
JP4896220B2 (ja) 2012-03-14
WO2008139703A1 (ja) 2008-11-20
US20100086615A1 (en) 2010-04-08
CA2685054A1 (en) 2008-11-20
JPWO2008139703A1 (ja) 2010-07-29
ES2425969T3 (es) 2013-10-18
KR101530393B1 (ko) 2015-06-19
CN101668542B (zh) 2012-06-27
EP2140882A1 (en) 2010-01-06
KR20100015758A (ko) 2010-02-12
CA2685054C (en) 2014-11-04
EP2140882B1 (en) 2013-08-14
PT2140882E (pt) 2013-09-30

Similar Documents

Publication Publication Date Title
IL207892A0 (en) Agent for treating disease
GB2465897B (en) Respiratory disease treatment
HK1151533A1 (zh) 種治療疾病的試劑
ZA201007215B (en) Agent for treating disease
IL194076A0 (en) Imidazolothiazole compounds for the treatment of disease
IL230335A (en) A drug used to treat cartilage disease
HK1141708A1 (en) Agent for treatment of pulmonary disease
EP2160100A4 (en) TREATMENT OF GRAFT REJECTION DISEASE
EP2271352A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASE
GB0700972D0 (en) Treatment of inflammatory disease
PL2056858T3 (pl) Leczenie stanów chorobowych płuc
EP2210621A4 (en) COMPOSITION FOR THE TREATMENT OF JOINT DISEASES
GB0720976D0 (en) Treatment of inflammatory disease
EP2123299A4 (en) THERAPEUTIC AGENT FOR INTERSTITIAL PULMONARY DISEASE COMPRISING ANTI-HMGB-1 ANTIBODY
GB0701456D0 (en) Treatment for respiratory disease
GB2447884B (en) Treatment for skin disease
EP2210878A4 (en) THERAPEUTIC AGENT AGAINST TRPV1-MEDIATED DISEASES
GB0623740D0 (en) Treatment of disease
GB0817859D0 (en) Treatment of proteostatic disease
GB0819543D0 (en) Treatment of proteostatic disease
GB0716840D0 (en) Treatment of cardiovascular disease
GB0817810D0 (en) Agent for treating disease
GB0817809D0 (en) Agent for treating disease
GB0817811D0 (en) Agent for treating disease
GB0823568D0 (en) Respiratory disease treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210423